Therapeutics case studies

Learn more on how we bring life changing therapies to market.

Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.

Chronic Myeloid Leukaemia

As a result of the multifaceted communication approach with sites and a strong partnership between ICON and sponsor, the study met its protocol-specified enrolment goal just 9 days beyond contracted Last Patient In date (LPI).

Leveraging Immuno-Oncology real world data

ICON supported a randomised phase 3 study to examine the study drug in combination with nivolumab vs chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.

Successful adaptation to complex dose escalation

ICON was selected by a mid-size biotech company to support a phase 1 dose escalation and cohort expansion study of an immune checkpoint inhibitor, in patients with advanced solid tumors. Mid-study, the sponsor was acquired by a large pharma company to which ICON has efficiently supported the transition to the evolving sponsor business model and operations.

A small biotech success story

A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.

Creating a pool of high-quality CRA talent

An accelerated training program for Early Development Oncology CRAs was required to significantly increase the cohort of CRA talent across 7 countries globally.

Strategic site management

A top ten pharmaceutical company needed clinical site support in an FSP model as it changed its pipeline to focus on complex oncology studies. The introduction of a Site Engagement Liaison delivered significant efficiencies and reduced risk.

Transforming a partnership into a blended model

A 10-year existing FSO partnership was expanded to incorporate a blended model to aid sourcing niche roles across multiple geographies whilst the sponsor maintained greater control of key areas.

Phase 3 Multiple Myeloma study

A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.

Phase 3 unresectable biliary tract carcinoma study

A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.

Accelerating CAR T Study Start-ups

ICON partnered with a top biopharma in the clinical development of CAR T for patients with relapsed and/or refractory Multiple Myeloma (BCMA construct) and B-cell Lymphomas (CD19 construct).